At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 401 enrolled

Drug / intervention

SCH 497079 +1 moredrug

Likely dose

SCH 497079 100 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00642993

NCT00642993Phase 2Completed

Compare CT.gov

A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Subjects

Merck Sharp & Dohme LLC·interventional·Posted Mar 25, 2008·Updated Sep 10, 2018

In Brief

A Phase 2 clinical trial evaluating SCH 497079 and Placebo for Obesity and 2 related conditions. Completed, enrolled 401 participants.

Detailed Summary

The purpose of this study is to evaluate the effect of SCH 497079 on weight in obese and overweight participants. The primary measure of effectiveness is the change in body weight during treatment. Additional measures include waist circumference and body mass index (BMI). In addition, the safety of SCH 497079 in obese and overweight participants will be evaluated. The primary hypothesis is that treatment with SCH 497079 will be more efficacious than that with placebo with respect to the primary efficacy variable.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsObesity, Overweight, Body Weight

Countries--

Collaborators--

Timeline

Phase 2CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedMar 2008

Enrollment StartJun 2008

Primary CompletionJan 2009

TodayJul 2026

First PostedMar 25, 2008

Enrollment StartJun 9, 2008

Primary CompletionJan 30, 2009

TodayJul 2, 2026

Enrollment to primary: 8 monthsPosted 18.3 years ago

Interventions

SCH 497079drug

100 mg capsule administered orally

Placebodrug

Placebo capsules matching SCH 497079 administered orally